SCYNEXIS Reports $20.6 Million Revenue Growth and Advances SCY-247 Development

SCYNEXIS, Inc. reported significant financial developments in its annual 10-K filing for the fiscal year ended December 31, 2025. The company generated total revenue of $20.6 million, a substantial increase from $3.7 million in the previous year, primarily driven by a cumulative catch-up of $17.2 million in license agreement revenue related to its collaboration with GlaxoSmithKline (GSK). Product revenue from the sale of BREXAFEMME, an antifungal treatment, contributed $1.4 million, marking the first revenue from product sales since its launch. Despite this revenue growth, SCYNEXIS reported a net loss of $8.6 million, a notable improvement from the $21.3 million loss recorded in 2024.

In terms of operational changes, SCYNEXIS has made strides in its clinical development pipeline, particularly with its antifungal candidate SCY-247. The company completed the single and multiple ascending dose portions of a Phase 1 study involving 88 healthy subjects, which demonstrated favorable safety and pharmacokinetic profiles. The FDA has granted SCY-247 Qualified Infectious Disease Product status and Fast Track designation, which could provide regulatory exclusivity for at least ten years if approved. The company plans to initiate a Phase 1 study of an intravenous formulation of SCY-247 in early 2026, with a Phase 2 study targeting invasive candidiasis expected later that year.

SCYNEXIS's strategic partnership with GSK has evolved, particularly following the termination of the MARIO study, which was part of their collaboration. The company received $24.8 million in non-refundable payments from GSK as part of a binding memorandum of understanding to wind down the study. This agreement does not alter the potential milestones and royalties payable to SCYNEXIS under the GSK License Agreement, which includes royalties on sales of BREXAFEMME for vulvovaginal candidiasis.

As of December 31, 2025, SCYNEXIS had cash, cash equivalents, and investments totaling approximately $56.3 million, down from $75.1 million the previous year. The company reported an accumulated deficit of $385.1 million and anticipates continued operating losses as it invests in the development of SCY-247 and other product candidates. The company is actively seeking additional capital through equity offerings, debt financing, or strategic collaborations to support its ongoing operations and development efforts.

Looking ahead, SCYNEXIS remains focused on addressing unmet medical needs in the antifungal space, particularly with the development of SCY-247. The company is aware of the challenges it faces, including the need for regulatory approvals and market acceptance of its products. The management's outlook emphasizes the importance of securing additional funding and successfully navigating the complexities of drug development and commercialization in a competitive market.